Remedor Biomed

Company Overview

Snapshot

Founded in November 2009 by Saher Hamed, M.D., Ph.D., Remedor Biomed operates with 1–10 employees. The company has secured one disclosed funding round. In December 2009, it received a grant from the Israel Innovation Authority.

Business overview

Remedor Biomed is a clinical-stage biopharmaceutical company focused on developing medications for skin wounds that are resistant to current treatment options. The company's core technology platform utilizes a proprietary topical biologic, WOUNDAGEL, based on a naturally occurring glycoprotein, erythropoietin, delivered via a smart hydrogel-matrix. This platform is designed to be active across all phases of the healing process and can withstand extreme temperature fluctuations. Remedor Biomed primarily targets complex wounds such as diabetic foot ulcers and deep burn wounds, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.

Strategic signal

In September 2018, Remedor Biomed was assigned patents, indicating a continued focus on intellectual property protection and the advancement of its wound healing technologies. This signals to investors a commitment to securing its innovative approach in the competitive biopharmaceutical landscape, reinforcing the company's long-term strategic positioning in regenerative medicine.

Company Intelligence Q&A

When was Remedor Biomed founded?

Remedor Biomed was founded in November 2009.

Who is the founder of Remedor Biomed?

Saher Hamed, M.D., Ph.D. is the founder and CEO of Remedor Biomed.

What is Remedor Biomed's primary focus?

Remedor Biomed focuses on developing medications for complex skin wounds, such as diabetic foot ulcers and deep burn wounds, that do not respond well to existing treatments.

Has Remedor Biomed secured any grants?

Yes, in December 2009, Remedor Biomed secured a grant from the Israel Innovation Authority.

What is the core technology behind Remedor Biomed's products?

Remedor Biomed's core technology platform is based on a proprietary topical biologic formulation containing erythropoietin, delivered via a smart hydrogel-matrix, designed to be active in each phase of the healing process.